SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Weibull Caroline E)
 

Search: WFRF:(Weibull Caroline E) > Comorbidities and s...

  • Glimelius, Ingrid,1975-Karolinska Institutet,Uppsala universitet,Karolinska Institute,Department of Medicine, Division of Clinical Epidemiology, Karolinska Institutet and Karolinska University Hospital,Uppsala University Hospital,Experimentell och klinisk onkologi (author)

Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • 2019-11-13
  • Wiley,2019

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:59e6632b-d362-4342-9748-295562a35cd7
  • https://lup.lub.lu.se/record/59e6632b-d362-4342-9748-295562a35cd7URI
  • https://doi.org/10.1111/bjh.16317DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-397705URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:142217078URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • The prognosis for mantle cell lymphoma (MCL) remains poor. Our aim was to assess the impact of comorbidities on survival and causes of death. For 1,385 MCL patients (1,009 males, 376 females) diagnosed in 2000–2014 (median age 71 years, range 22–96) comorbidities ≤ 10 years of diagnosis were classified according to the Charlson comorbidity index (CCI; 0, 1, 2+). Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated to compare lymphoma-specific and all-cause mortality rates. Model-based predictions were used to obtain probabilities of death. Overall, 44% had any comorbidity (CCI 1+) and 28% severe comorbidity (CCI 2+). Over a median follow-up of 3·7 years (range 0–16), 633 (46%) died, the majority (76%) from lymphoma. Severe comorbidity was independently associated with higher all-cause [hazard ratio (HR) = 1·52; 95% CI: 1·24–1·85) and lymphoma-specific mortality (HR = 1·31; 95% CI: 1·04–1·65). Particularly among patients with connective tissue, renal and psychiatric diseases, and dementia. Among females with any comorbidity, non-lymphoma deaths represented a larger proportion of all deaths, compared to males with any comorbidity. In general, more efficient lymphoma treatments need to be considered also for patients with severe comorbidity. However, among females with any comorbidity, the likelihood of non-lymphoma death was still considerable, perhaps favouring a more liberal use of a “wait and watch” approach.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Smedby, Karin E.Karolinska Institutet,Karolinska Institute,Karolinska University Hospital (author)
  • Eloranta, SandraKarolinska Institute,Karolinska University Hospital (author)
  • Jerkeman, MatsLund University,Lunds universitet,Skåne University Hospital(Swepub:lu)onk-mje (author)
  • Weibull, Caroline E.Karolinska Institutet,Karolinska Institute,Karolinska University Hospital (author)
  • Karolinska InstituteDepartment of Medicine, Division of Clinical Epidemiology, Karolinska Institutet and Karolinska University Hospital (creator_code:org_t)

Related titles

  • In:British Journal of Haematology: Wiley0007-10481365-2141

Internet link

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view